Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Saint-Herblain (France), October 27, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe.
Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the upcoming Phase 3 trial outcomes for VLA15, the Company’s Lyme disease vaccine candidate, which is partnered with Pfizer. If successful, Pfizer aims to submit applications for U.S. and European market authorization in 2026. Pending approval, Valneva expects Pfizer to launch the vaccine in the second half of 2027.
Guggenheim 2nd Annual Healthcare Innovation Conference
Date/Time: November 10, 10:30am EST
Format: Fireside chat and investor meetings
Location: Boston, Massachusetts
Stifel 2025 Healthcare Conference
Date/Time: November 11, 9:20am EST
Format: Fireside chat and investor meetings
Location: New York, New York
Jefferies London Healthcare Conference
Date/Time: November 19, 2:00pm GMT
Format: Fireside chat and investor meetings
Location: London, United Kingdom
Webcast Link:
A replay of the webcast will be available following the live events in the “Investor” section of the Valneva website at .
Institutional investors who would like to meet with Valneva management at any of the below conferences are asked to submit a request to their representative at the respective bank.
About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at .
| Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 | Joshua Drumm, Ph.D. VP, Global Investor Relations M 20 |
Forward Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates, to regulatory approval of product candidates and review of existing products, and financial guidance including projected product sales, total revenue and total R&D investments. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Attachment
